Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab + Non-platinum Chemo in PARPi-Resistant Ovarian Cancer
NCT05407584Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Jul 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Yonsei University. Status: unknown.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05407584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407584.